Pertussis Market Insights 2025–2034: Emerging Vaccines and Treatment Landscape

Pertussis Market Overview: Trends, Treatments, and Emerging Opportunities

The Pertussis Market is poised for steady growth, driven by rising awareness of the disease and advancements in more effective interventions. Key players in the sector, including Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, and BioNet, are leading the charge in developing innovative vaccines and therapies. The market presents significant potential for expansion, particularly with new vaccine introductions.

Market Insights and Scope

DelveInsight’s report, “Pertussis Market Insights, Epidemiology, and Market Forecast – 2034,” provides a detailed analysis of the Pertussis Drugs Market. Covering historical and projected epidemiology, treatment patterns, emerging therapies, and market dynamics, the report spans the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. The study focuses on forecasts from 2024–2034 and offers comprehensive data on Pertussis Market Size, therapy segmentation, and the competitive landscape.

Understanding Pertussis: Disease and Diagnosis

Pertussis, also known as whooping cough, is a severe respiratory infection caused by Bordetella pertussis. The disease progresses through three stages: catarrhal, paroxysmal, and convalescent. Accurate diagnosis can be challenging, with methods including culture, PCR, paired sera, and single sera tests—the paired sera test being the most reliable.

Prevention and Treatment

Vaccination remains the cornerstone of Pertussis Therapeutics Market strategies. In the U.S., DTaP and Tdap vaccines are widely administered, with adolescents and adults recommended to receive at least three doses. Treatment primarily involves macrolide antibiotics such as erythromycin, clarithromycin, or azithromycin, though side effects may sometimes affect adherence. Supportive care—oxygen therapy, hydration, and avoiding respiratory irritants—is also essential.

Epidemiology and Vaccine Coverage

The report provides in-depth epidemiology across the seven major markets (7MM). In 2022, about 19 million individuals were vaccinated in the U.S., with 5 million adults receiving booster doses. Across the 7MM, approximately 34 million people were vaccinated, a figure expected to rise due to increased awareness, updated immunization guidelines, and the introduction of new vaccines.

Key Vaccines and Emerging Therapies

  • ADACEL (Sanofi Pasteur): Trivalent booster for pertussis, tetanus, and diphtheria, available in 55 countries.

  • BOOSTRIX (GSK): Recommended for individuals aged 10+, including maternal immunization programs.

Emerging Vaccines:

  • BPZE1 (ILiAD Biotechnologies): Intranasal booster in Phase IIb, with FDA Fast Track designation.

  • BK1310/MT-2355 (Mitsubishi Tanabe Pharma): 5-in-1 combination vaccine planned for launch in Japan.

Market Outlook

Maintaining complete immunization remains crucial to controlling pertussis. While infant and childhood vaccination rates are high across the 7MM, adult booster compliance remains low. The Pertussis Treatment Market is competitive in the U.S. and Europe, with vaccines like PEDIARIX, PENTACEL, and Vaxelis driving growth, while Mitsubishi leads the Japanese market with TETRABIK. The total Pertussis Market Size in the 7MM reached $3.5 billion in 2022, with the U.S. as the largest contributor.

Vaccine Adoption, Pipeline, and Competitive Landscape

The report evaluates adoption rates for newly launched and upcoming vaccines, patient uptake trends, sales performance, and market share. Insights into pipeline development, collaborations, patent filings, and regulatory progress provide a strategic overview for stakeholders.

Reimbursement scenarios are also assessed to identify economically attractive markets and potential challenges. Expert opinions from KOLs validate current and emerging treatments, market trends, and unmet needs. Additionally, competitive intelligence, market entry strategies, and SWOT analyses help inform decisions for Pertussis Companies and investors.
Latest Reports
Acute Pyelonephritis Market | Asperger Syndrome Market | Attention Deficit Hyperactivity Disorder Adhd Market | Cardiopulmonary Management Device Market | Childhood Atropine For Myopia Progression Market | Cholangiocarcinoma Market | Dyspepsia Market | Emphysema Market | Genital Herpes Market | Growth Hormone Deficiency Market | Guillain-barré Syndrome Market | Hairy Cell Leukemia Market | Intestinal Obstruction Market | Malignant Fibrous Histiocytoma Market | Menopause Market | Metabolic Acidosis Market | Multiple Myeloma Market | Neurostimulation Devices Market 

Comments

Post a Comment

Popular posts from this blog

Top 10 Pharmaceutical Market Intelligence Consultants Worldwide

  Top 10 Pharmaceutical Market Intelligence Consultants Worldwide  Competitors is not just an advantage—it’s a necessity. For healthcare executives, pharmaceutical companies, and investors, accurate and timely Competitive Intelligence (CI) is crucial for strategic decision-making. CI consulting firms provide organizations with actionable insights, enabling informed decisions on product development, market entry, and investment opportunities. Here, we present the top 10 CI consulting firms that have consistently demonstrated expertise, reliability, and value in the competitive intelligence space. 1. Frost & Sullivan Frost & Sullivan has built a solid reputation as a global growth consultancy, providing comprehensive market research and CI services. Their expertise spans multiple industries, including healthcare, life sciences, and technology. By combining rigorous data analytics, proprietary research methodologies, and market foresight, Frost & Sullivan empowers or...
Read more

Revolutionizing Pharma with CI Clinical Trial Intelligence

  Revolutionizing Pharma with CI Clinical Trial Intelligence CI Clinical Trial: Driving Pharma CI 2024 with Intelligence-Led Innovation In the fast-evolving pharmaceutical landscape, Competitive Intelligence (CI) has emerged as a crucial driver of success, especially in the context of clinical trials. A CI clinical trial leverages the power of data, insights, and analytics to inform key business decisions, track market movements, monitor competitor activities, and enhance strategic outcomes. As we move into Pharma CI 2024 , understanding the role of competitive intelligence in clinical trial planning and execution is more critical than ever. This article explores the importance of CI clinical trials, the evolving trends in pharma competitive strategy , the value of primary competitive intelligence , and the role of competitive ad tracking in modern pharmaceutical operations. What Is a CI Clinical Trial? A CI clinical trial involves the integration of competitive intelligence ph...
Read more

The Rising Impact of PCSK9 Inhibitors on Hypercholesterolemia Treatment

  PCSK9 Inhibitors: Revolutionizing Lipid-Lowering Therapy The global PCSK9 inhibitors market has witnessed significant growth over the past decade, driven by the rising prevalence of hypercholesterolemia and cardiovascular diseases worldwide. PCSK9 inhibitors represent a novel class of therapeutics designed to lower low-density lipoprotein cholesterol (LDL-C) levels in patients who are either intolerant to traditional statins or fail to achieve optimal lipid control with conventional therapy. The expanding PCSK9 inhibitors drugs market highlights the growing importance of these therapies in the management of cardiovascular risk. Overview of PCSK9 Inhibitors Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme that plays a pivotal role in cholesterol metabolism. By binding to LDL receptors on liver cells, PCSK9 leads to their degradation, reducing the liver’s capacity to remove LDL cholesterol from the blood. PCSK9 inhibitors work by blocking this interaction, there...
Read more